Hypertensive emergencies in Asia: A brief review

Praew Kotruchin, Thanat Tangpaisarn, Thapanawong Mitsungnern, Apichard Sukonthasarn, Satoshi Hoshide, Yuda Turana, Saulat Siddique, Peera Buranakitjaroen, Minh Van Huynh, Yook Chin Chia, Sungha Park, Chen Huan Chen, Jennifer Nailes, Jam Chin Tay, Ji Guang Wang, Kazuomi Kario

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Hypertensive emergency is one of the most challenging conditions to treat in the emergency department (ED). From previous studies, about 1%–3% of hypertensive individuals experienced hypertensive emergencies. Its prevalence varied by country and region throughout Asia. Asian populations have more different biological and cultural backgrounds than Caucasians and even within Asian countries. However, there is a scarcity of research on clinical features, treatment, and outcomes in multinational Asian populations. The authors aimed to review the current evidence about epidemiology, clinical characteristics and outcomes, and practice guidelines in Asia. Five observational studies and nine clinical practice guidelines across Asia were reviewed. The prevalence of hypertensive emergencies ranged from.1% to 1.5%. Stroke was the most common target organ involvement in Asians who presented with hypertensive emergencies. Although most hypertensive emergency patients required hospitalization, the mortality rate was low. Given the current lack of data among Asian countries, a multinational data repository and Asian guidelines on hypertensive emergency management are mandatory.

Original languageEnglish
Pages (from-to)1226-1235
Number of pages10
JournalJournal of Clinical Hypertension
Issue number9
Publication statusPublished - 2022 Sept

Bibliographical note

Funding Information:
The authors would like to thank the Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University for their support. The authors would also like to give our sincere gratitude to the HOPE ASIA network for this research opportunity and for sustaining hypertension-related initiatives in the region.

Funding Information:
S Siddique has received honoraria from Bayer, Getz Pharma, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Hilton Pharma, Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, and ICI. YC Chia has received unrestricted educational grants from Viatris and Omron and from Medtronic for activities of the Malaysian Society for World Action on Salt, Sugar, and Health (MyWASSH). YC Chia also has received speaker honoraria from Medtronic, Astra‐Zeneca, Omron, and Xepa‐Sol. S Park received lecture fees from Pfizer, Boryoung, Hanmi, Daewoong, Donga, Celltrion, Servier, Daiichi Sankyo, and Daewon. S Park also received a research grant from Daiichi Sankyo. All other authors had no competing interests.

Publisher Copyright:
© 2022 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Hypertensive emergencies in Asia: A brief review'. Together they form a unique fingerprint.

Cite this